Medopad, a U.K.-based medical firm, and China-based Tencent Holdings have teamed up on a project that will attempt to harness artificial intelligence in the diagnosis of Parkinson’s disease.
Denali Therapeutics stock climbed 11 percent after the release of positive data from the company’s Phase I clinical trial of DNL201 in Parkinson’s disease.
Seven months after Prevail Therapeutics launched, the New York-based company secured $75 million in Series A financing to support the development of gene therapies for Parkinson’s disease and other neurodegenerative diseases.
Pfizer released an update of the company’s pipeline, including eight different discontinued projects in the field of neuroscience.
Pfizer Inc. is abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease.
Denali Therapeutics – launched in May 2015 by three former Genentech researchers – went public, raising $250 million with shares priced at $18.
Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.
The U.S. FDA turned down Acorda Therapeutics’ New Drug Application for Inbrija, which was being evaluated for OFF periods in Parkinson’s disease.
AstraZeneca is to receive up to $400 million from Takeda after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson’s disease.
The FDA approved Adamas Pharmaceuticals Inc’s treatment for a side effect caused by a commonly prescribed Parkinson’s drug.
